Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team.


Journal

Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150

Informations de publication

Date de publication:
05 2021
Historique:
received: 13 11 2020
revised: 04 01 2021
accepted: 28 01 2021
entrez: 7 4 2021
pubmed: 8 4 2021
medline: 18 9 2021
Statut: ppublish

Résumé

This study investigates the specific morbidity of rectosigmoid resection (RSR) during Visceral-Peritoneal Debulking (VPD) in a consecutive series of patients with stage IIIC-IV ovarian cancer and compares the results of the colo-rectal vs. the gynaecologic oncology team. All patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV ovarian cancer who had VPD and RSR were included in the study. Between 2009 and 2013 all operations were performed by the gynecologic oncology team alone (group 1). Since 2013 the RSR was performed by the colorectal team together with the gynecologic oncologist (group 2). All pre-operative information and surgical details were compared to exclude significant bias. Intra- and post-operative morbidity events were recorded and compared between groups. One hundred and sixty-two patients had a RSR during VPD, 93 in group 1 and 69 in group 2. Groups were comparable for all pre-operative features other than: albumin (1<2) hemoglobin (2<1) and up-front surgery (1>2). Overall morbidity was 33% vs. 40% (p=0.53), bowel specific morbidity 11.8% vs. 11.5% (p=0.81), anastomotic leak 4.1% vs. 6.1% (p=0.43) and re-operation rate 9.6% vs. 6.1% (p=0.71) in groups 1 and 2, respectively. None of them were significantly different. The rate of bowel diversion was 36.5% in group 1 vs. 46.3% in group 2 (p=0.26). Our study failed to demonstrate any significant difference in the morbidity rate of RSR based on the team performing the surgery. These data warrant further investigation as they are interesting with regards to education, finance, and medico-legal aspects.

Identifiants

pubmed: 33825357
pii: 32.e42
doi: 10.3802/jgo.2021.32.e42
pmc: PMC8039168
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e42

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Gynecol Oncol. 2018 Jan;148(1):74-78
pubmed: 29169615
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
J Gynecol Oncol. 2019 Mar;30(2):e25
pubmed: 30740956
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Gynecol Oncol. 2006 Dec;103(3):977-84
pubmed: 16837030
Gynecol Oncol. 2017 Mar;144(3):564-570
pubmed: 28073597
Gynecol Oncol. 2001 Nov;83(2):286-91
pubmed: 11606086
Gynecol Oncol. 1998 May;69(2):103-8
pubmed: 9600815
Healthcare (Basel). 2019 Jul 03;7(3):
pubmed: 31277282
Gynecol Oncol. 2001 Jan;80(1):79-84
pubmed: 11136574
Curr Opin Obstet Gynecol. 2015 Aug;27(4):291-6
pubmed: 26107782
PLoS One. 2012;7(7):e39415
pubmed: 22844394
J Gynecol Oncol. 2010 Jun;21(2):75-80
pubmed: 20613895
Ann Surg. 2016 Jan;263(1):e1-2
pubmed: 26672509
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Br J Surg. 2005 Jan;92(1):101-6
pubmed: 15635697
Gynecol Oncol. 2015 Aug;138(2):252-8
pubmed: 26003142
Eur J Gynaecol Oncol. 2014;35(4):400-7
pubmed: 25118481
Gynecol Oncol. 2006 Nov;103(2):667-72
pubmed: 16797684
Gynecol Oncol. 2012 Aug;126(2):220-3
pubmed: 22555105
Ann Surg Oncol. 2012 Dec;19(13):4059-67
pubmed: 22766983
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Gynecol Oncol. 2001 Oct;83(1):115-20
pubmed: 11585422
J Gynecol Oncol. 2018 Jul;29(4):e60
pubmed: 29770630
World J Gastrointest Surg. 2012 Sep 27;4(9):208-13
pubmed: 23293735
Eur J Gynaecol Oncol. 2011;32(4):419-22
pubmed: 21941966

Auteurs

Roberto Tozzi (R)

Department of Gynaecologic Oncology, Churchill Hospital, Oxford University, Oxford, UK.
Nuffield Department of Women & Reproductive Health, University of Oxford, Oxford, UK. roberto.tozzi@wrh.ox.ac.uk.

Gaetano Valenti (G)

Department of Gynaecologic Oncology, Churchill Hospital, Oxford University, Oxford, UK.

Daniele Vinti (D)

Department of Gynaecologic Oncology, Churchill Hospital, Oxford University, Oxford, UK.

Riccardo Garruto Campanile (RG)

Department of Gynaecologic Oncology, Churchill Hospital, Oxford University, Oxford, UK.

Massimo Cristaldi (M)

Department of Colorectal Surgery, Harley Street Medical Centre, Abu Dhabi, UAE.

Federico Ferrari (F)

Department of Gynaecologic Oncology, Churchill Hospital, Oxford University, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH